南非制药集团阿斯彭制药（Aspen Pharmacare）首席执行官周二表示，公司开发的诺和诺德热门降糖药Ozempic（司美格鲁肽） 仿制药，有望在今年第二季度或第三季度在加拿大获得注册批准。

　　“我们正在收到监管机构的反馈。按目前情况判断，我们有望在今年二季度末或三季度—— 也就是 5 月至 9 月之间 —— 获得注册批准。” 斯蒂芬・萨德（Stephen Saad）对路透社表示。

　　今年 1 月，诺和诺德用于糖尿病治疗的司美格鲁肽（semaglutide）专利在加拿大到期，阿斯彭希望成为加拿大首批推出 Ozempic 仿制药的企业之一。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：郭明煜

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.